Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction.
Publication/Presentation Date
7-3-2025
Abstract
BackgroundLeft heart failure is the most common cause of pulmonary hypertension and increases morbidity and mortality. We investigate the use of canagliflozin, an antidiabetic Sodium-glucose Cotransporter-2 Inhibitor, which is first-line therapy in congestive heart failure, on pulmonary fibrosis in a porcine model of chronic myocardial ischemia.MethodologySixteen Yorkshire swine, eight in a normal diet control arm (NDC) and eight in the canagliflozin arm (CAN), underwent left thoracotomy and ameroid constrictor placement on the left circumflex artery. Seven weeks after placement, the swine underwent harvest procedure. During harvest, left ventricular contractility was quantified by direct left ventricular pressure-volume loops. Protein expression was quantified by immunoblotting and Masson's trichrome staining was utilized to assess perivascular collagen deposition.ResultsAnalysis of left ventricular ejection fraction demonstrated no significant difference between CAN and NDC. Western blot analysis demonstrated increases in TGFβ signaling pathways with decreased free TGFβ and TGFβ monomers in CAN pigs (
First Page
2184923251352222
Last Page
2184923251352222
ISSN
1816-5370
Published In/Presented At
Kanuparthy, M., Harris, D. D., Broadwin, M., Stone, C., Hamze, J., Yalamanchili, K., Sabe, S., & Sellke, F. W. (2025). Canagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces lung fibrosis in left heart dysfunction. Asian cardiovascular & thoracic annals, 2184923251352222. Advance online publication. https://doi.org/10.1177/02184923251352222
Disciplines
Medicine and Health Sciences
PubMedID
40605641
Department(s)
Fellows and Residents, Department of Surgery
Document Type
Article